KPTI
$7.63-0.10 (-1.29%)
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Recent News
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations
Karyopharm Therapeutics is under fresh scrutiny as analysts reaffirm a $28 price target while keeping the central fair value estimate steady at $15.33. That target is being framed largely around confidence in selinexor, the Phase 1 myelofibrosis data, and the projected US$800m to US$850m frontline opportunity, with bulls and bears divided on how much weight to assign to early stage results and asset concentration. Read on to see how to interpret these moving pieces and follow the evolving...
Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting
Karyopharm Therapeutics (NASDAQ:KPTI) held a virtual special meeting of stockholders on Feb. 18, 2026, to vote on two proposals outlined in the company’s proxy materials. The meeting was chaired by President, CEO, and Director Richard Paulson, with Chief Legal Officer Michael Mano serving as secreta
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report
The investors in Karyopharm Therapeutics Inc. 's ( NASDAQ:KPTI ) will be rubbing their hands together with glee today...
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ...
Karyopharm Therapeutics Inc (KPTI) reports strong revenue growth and strategic advancements in myelofibrosis, despite facing financial hurdles and increased competition.